Dual-Mechanism Drop Wins FDA Approval - Takeaways - MDSpire

Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

  • February 2, 2026

  • 2 min

Share

  • 1

    YUVEZZI™ is the first FDA-approved dual-agent eye drop for treating presbyopia in adults.

  • 2

    The formulation combines carbachol and brimonidine tartrate to improve near visual acuity while preserving distance vision.

  • 3

    FDA approval was based on two Phase 3 trials, BRIO I and BRIO II, involving over 800 patients.

  • 4

    YUVEZZI demonstrated significant improvements in near vision without serious adverse events during extensive safety studies.

  • 5

    The product is expected to be commercially available in the US by the second quarter of 2026.

Original Source(s)

Dual-Mechanism Drop Wins FDA Approval

  • February 2, 2026

Related Content

The Latest News in Ophthalmology

A look at the latest news in ophthalmology

  • July 1, 2025

  • 9 min
PC-IOL Bulletin

Presbyopia-correcting intraocular lenses deliver a substantial lifestyle improvement, so offering them is becoming the new standard of care among cataract surgeons.

A Year of First Endeavors

An introduction to the October 2025 Dry Eye Disease issue by Jane T. Shuman, Editor in Chief.